Preferred Label : Stathmin Pathway;
NCIt related terms : Stathmin and breast cancer resistance to antimicrotubule agents;
Alternative definition : BIOCARTA: Stathmin is a ubiquitous, cytosolic 19-kDa protein, that is phosphorylated
on up to four sites in response to many regulatory signals within cells. Its molecular
characterization indicates a functional organization including an N-terminal regulatory
domain that bears the phosphorylation sites linked to a putative alpha-helical binding
domain predicted to participate in coiled-coil, protein-protein interactions. In addition
to the protein kinases that phosphorylate Stathmin such as CaMK, MAPK, p34cdc2, PKA,
a few other proteins have been suggested to interact with stathmin in vivo. One of
them was identified as BiP, a member of the hsp70 heat-shock protein family. Another
is a previously unidentified, putative serine/threonine kinase, KIS, which might be
regulated by stathmin or, more likely, be part of the kinases controlling its phosphorylation
state. Finally, proteins CC1 and CC2, predicted to form alpha-helices participating
in coiled-coil interacting structures. It has been suggest that the action of antimicrotubule
drugs can be affected by stathmin in at least two ways: (a) altered drug binding;
and (b) growth arrest at the G2 to M boundary. Mutant p53 breast cancers exhibiting
high levels of stathmin may be resistant to antimicrotubule agents. (This definition
may be outdated - see the DesignNote.);
NCIt note : The BIOCARTA Definition (ALT_DEFINITION) for this pathway concept was provided by
BioCarta. This property was not created by, nor is it maintained by the NCI Thesaurus
staff. Additionally, BioCarta is no longer updating its pathway data; thus, the BIOCARTA
Definition might be outdated or inaccurate. Please see the Terms and Conditions for
Use at http://www.biocarta.com/.;
Biocarta ID : h_stathminPathway;
Origin ID : C39239;
UMLS CUI : C1514959;
Semantic type(s)
has_gene_product_element
pathway_has_gene_element